---
title: "Sanofi faces stock decline as CEO change announced, market cap of $113.6B, shares down 4.5%, near 52-week low."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275910122.md"
description: "Sanofi SA's shares fell 4.5% in premarket trading following the announcement of CEO Paul Hudson's departure, with a market cap of $113.6 billion. The stock is nearing its 52-week low of $44.62-$60.12. Belén Garijo will succeed Hudson after the Annual General Meeting on April 29. The company aims to enhance its strategy and innovation in R&D, despite ongoing challenges in its drug pipeline. In Q4 2025, sales of Dupixent rose by 32.2% to 4.2 billion euros."
datetime: "2026-02-13T13:29:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275910122.md)
  - [en](https://longbridge.com/en/news/275910122.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275910122.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275910122.md) | [繁體中文](https://longbridge.com/zh-HK/news/275910122.md)


# Sanofi faces stock decline as CEO change announced, market cap of $113.6B, shares down 4.5%, near 52-week low.

Sanofi SA (NASDAQ: SNY) shares are experiencing a decline in the premarket session on Friday due to leadership changes amidst ongoing issues in its drug pipeline. The French drugmaker, with a market cap of approximately $113.6 billion, closed 4.5% lower on Thursday, moving closer to the lower end of its 52-week range of $44.62-$60.12. The departure of CEO Paul Hudson was announced by the board, with Belén Garijo set to succeed him. Hudson's last day as CEO is scheduled for February 17, and Garijo will assume the role after the Annual General Meeting on April 29. Sanofi aims to strengthen its strategy and innovation capacity, particularly in Research & Development. In the fourth quarter of 2025, Sanofi saw a significant 32.2% increase in sales of its leading drug, Dupixent, amounting to 4.2 billion euros.

### Related Stocks

- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [Sanofi (SNYNF.US)](https://longbridge.com/en/quote/SNYNF.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [Sanofi (SNY.US)](https://longbridge.com/en/quote/SNY.US.md)

## Related News & Research

- [How New CHMP Opinions on Dupixent and Acoziborole Will Impact Sanofi (ENXTPA:SAN) Investors](https://longbridge.com/en/news/278666481.md)
- [XY Capital Ltd Acquires Shares of 33,970 Sanofi $SNY](https://longbridge.com/en/news/279122080.md)
- [Brazil's EMS purchases Sanofi's Medley](https://longbridge.com/en/news/278113014.md)
- [Sanofi receives CHMP recommendation for Dupixent approval in Europe](https://longbridge.com/en/news/277451322.md)
- [Sanofi Wins Japan Orphan Status for Rilzabrutinib and Moves to Strengthen Governance](https://longbridge.com/en/news/278578865.md)